4//SEC Filing
McDonough John 4
Accession 0000899243-19-003306
CIK 0001492674other
Filed
Feb 11, 7:00 PM ET
Accepted
Feb 12, 4:47 PM ET
Size
9.2 KB
Accession
0000899243-19-003306
Insider Transaction Report
Form 4
McDonough John
DirectorPresident & CEO
Transactions
- Exercise/Conversion
Common Stock
2019-02-09+16,666→ 456,354 total - Sale
Common Stock
2019-02-11$3.36/sh−8,134$27,330→ 448,220 total - Exercise/Conversion
Restricted Stock Units
2019-02-09+16,666→ 16,667 total→ Common Stock (16,666 underlying)
Footnotes (4)
- [F1]Each restricted stock units ("RSU's") represents a contingent right to receive one share of the Issuer's common stock.
- [F2]The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2018.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $3.31 to $3.40. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]On February 9, 2017 the reporting person was granted 50,000 RSU's that vested in three equal annual installments beginning on February 9, 2018.
Documents
Issuer
T2 Biosystems, Inc.
CIK 0001492674
Entity typeother
Related Parties
1- filerCIK 0001615937
Filing Metadata
- Form type
- 4
- Filed
- Feb 11, 7:00 PM ET
- Accepted
- Feb 12, 4:47 PM ET
- Size
- 9.2 KB